The Keto/Paleo diet is "better than the rest" and not good for the planet.

Published Date: 08 Mar 2023

Plant-based vegetarian and vegan diets may have the lowest carbon footprint in the United States, but new data analysis shows fish-based pescatarian diets are the best.

Read Full News

Latest News

Where Does Ameluz PDT Fit Alongside Mohs Surgery? Neal Bhatia, MD

Where does Ameluz PDT fit next to Mohs surgery for skin cancer? Neal Bhatia, MD, on candidacy, adoption, and open questions.

7 Dermatology Headlines You Missed in September 2026

7 Dermatology Headlines You Missed in September 2026

EADV Congress 2026: Day 2 Recap—6 Headlines to Know

EADV Congress 2026: Day 2 Recap—6 Headlines to Know

What the FDA's Approval of Ameluz PDT Means for Skin Cancer Neal Bhatia, MD

What does FDA approval of Ameluz PDT for superficial BCC mean for dermatology? Neal Bhatia, MD, weighs in on the first-of-its-kind decision.

EADV Congress 2026: Day 1 Recap — 6 Headlines to Know Victoria Johnson

Check out highlights from news published on Day 1 of the EADV Congress 2026, spanning CSU, atopic dermatitis, HS, and more.

FDA News Recap: Novel Drug Approvals in Q3 2026

FDA News Recap: Novel Drug Approvals in Q3 2026

Todays Updates

8 Pulmonology Headlines You Missed in September 2026

8 Pulmonology Headlines You Missed in September 2026

Congress Passes ACT for ALS Reauthorization, Extending Research Programs Louie Pasculli

The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 extends federal support for ALS research and expanded access to investigational therapies, with additional provisions addressing clinical trial oversight and regulatory planning.

2026 Rachel Horne Prize Winner Sandra Vukusic, MD, PhD, on Advancing Women's Health in MS Isabella Ciccone, MPH, Sandra Vukusic, MD, PhD

The professor of neurology at the University of Lyon and 2026 Rachel Horne Prize Winner discussed pregnancy counseling, therapeutic inertia, and overlooked women's health issues in multiple sclerosis.

Tips for Clinicians Diagnosing Patients with Diverse Skin Types Mona Shahriari, MD, FAAD, Jennifer Soung, MD

Jennifer Soung, MD, and Mona Shahriari, MD, discuss diagnosing psoriasis in diverse skin tones and why severity scores overlook dyspigmentation.

AMETHYST: Litifilimab Sustains CLE Gains at 52 Weeks, With Victoria Werth, MD

AMETHYST: Litifilimab Sustains CLE Gains at 52 Weeks, With Victoria Werth, MD

EADV Congress 2026: Day 3 Recap—5 Headlines to Know

EADV Congress 2026: Day 3 Recap—5 Headlines to Know

Upadacitinib Tops Nemolizumab on Skin, Itch Targets in Indirect Analysis

Upadacitinib Tops Nemolizumab on Skin, Itch Targets in Indirect Analysis

Todays Updates

8 Pulmonology Headlines You Missed in September 2026

8 Pulmonology Headlines You Missed in September 2026

Congress Passes ACT for ALS Reauthorization, Extending Research Programs Louie Pasculli

The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 extends federal support for ALS research and expanded access to investigational therapies, with additional provisions addressing clinical trial oversight and regulatory planning.

2026 Rachel Horne Prize Winner Sandra Vukusic, MD, PhD, on Advancing Women's Health in MS Isabella Ciccone, MPH, Sandra Vukusic, MD, PhD

The professor of neurology at the University of Lyon and 2026 Rachel Horne Prize Winner discussed pregnancy counseling, therapeutic inertia, and overlooked women's health issues in multiple sclerosis.

Tips for Clinicians Diagnosing Patients with Diverse Skin Types Mona Shahriari, MD, FAAD, Jennifer Soung, MD

Jennifer Soung, MD, and Mona Shahriari, MD, discuss diagnosing psoriasis in diverse skin tones and why severity scores overlook dyspigmentation.

AMETHYST: Litifilimab Sustains CLE Gains at 52 Weeks, With Victoria Werth, MD

AMETHYST: Litifilimab Sustains CLE Gains at 52 Weeks, With Victoria Werth, MD

EADV Congress 2026: Day 3 Recap—5 Headlines to Know

EADV Congress 2026: Day 3 Recap—5 Headlines to Know

Upadacitinib Tops Nemolizumab on Skin, Itch Targets in Indirect Analysis

Upadacitinib Tops Nemolizumab on Skin, Itch Targets in Indirect Analysis

Latest News

Where does Ameluz PDT fit next to Mohs surgery for skin cancer? Neal Bhatia, MD, on candidacy, adoption, and open questions.

7 Dermatology Headlines You Missed in September 2026

EADV Congress 2026: Day 2 Recap—6 Headlines to Know

What does FDA approval of Ameluz PDT for superficial BCC mean for dermatology? Neal Bhatia, MD, weighs in on the first-of-its-kind decision.

Check out highlights from news published on Day 1 of the EADV Congress 2026, spanning CSU, atopic dermatitis, HS, and more.

FDA News Recap: Novel Drug Approvals in Q3 2026

News All Time

The Present and Future of Precision Medicine in Dermatology, With Peter Lio, MD Peter Lio, MD

Peter Lio, MD, discusses why precision medicine has advanced further in psoriasis than atopic dermatitis, and what oncology can teach dermatology.

FDA Approves First Oral Treatment of Dermatomyositis in Adult Patients Tim Smith

The approval adds brepocitinib (Lisraya), an oral JAK/TYK2 inhibitor, as the first agent specifically studied and approved for dermatomyositis in adults.

Competition, Burnout, and the Cost of Always Saying 'Yes' as a Clinician Adam Friedman, MD, FAAD

Adam Friedman, MD, traces dermatology's yes-first culture to residency competition, previewing an unrehearsed LEADderm 2026 negotiation exercise.

Tips on Saying 'No' as a Dermatology Leader, With Adam Friedman, MD Adam Friedman, MD, FAAD

Adam Friedman, MD, discusses saying no strategically as a career skill in a LEADderm 2026 table talk on managing opportunities.

How Failure Is the Stepping Stone to Success, With Lisa Swanson, MD Lisa A. Swanson, MD

Lisa Swanson, MD, on treating professional failure as a source of direction and resilience in her LEADderm 2026 talk.

Resilience in Medicine, HS Treatments, and the Oral JAK Pipeline Today Lisa A. Swanson, MD

Lisa Swanson, MD, on embracing failure in medicine and the oral JAK inhibitors advancing for hidradenitis suppurativa and alopecia areata.

6 Dermatology Headlines You Missed in August 2026 Tim Smith

A roundup of dermatology's biggest August headlines, from an FDA approval to conference previews and conversations on equity in care.

Skin Angels and the Atopic Dermatitis Pipeline, With Peter Lio, MD Peter Lio, MD

Peter Lio, MD, on Skin Angels, a dermatology-focused angel-investing group that has evaluated over 300 companies and funded more than 30.

Reaching Patients Online and Avoiding Burnout, With Steven Daveluy, MD Steven Daveluy, MD, FAAD

Steven Daveluy, MD, speaks on why dermatologists belong on social media, avoiding burnout in practice, and what excites him in HS treatment.

Why Dermatologists Should Have a Seat at the Investment Table, With Manju Dawkins, MD Manju Dawkins, MD

A dermatologist-turned-entrepreneur on why clinicians belong in dermatology's investment decisions, and what excites her about the field's direction.

How Skin Angels Backs Dermatology's Next Innovators, With Ross Levy, MD Ross M. Levy, MD

Ross Levy, MD, on how Skin Angels invests in dermatology innovation and where he sees the field heading over the next 5 - 10 years.

KT-621 Achieves Deep STAT6 Degradation, Initial Respiratory, Skin Gains Victoria Johnson

The oral STAT6 degrader achieved deep STAT6 suppression, up to 63% EASI reduction, and gains in asthma and rhinitis scores by week 4.

Dermatology's Path From Idea to Innovation, With Ross Levy, MD Ross M. Levy, MD

Ross Levy, MD, explains why the LEADderm Skin Angels panel matters and what dermatology innovation looks like in daily practice.

LEADderm 2026 Recap: 7 Interviews Dermatologists Should Know Tim Smith

A recap of 7 standout interviews from LEADderm 2026, covering molluscum care, HS pipeline data, precision medicine, and dermatology leadership.

Q&A: Why Saying 'No' is a Career Skill as a Clinician, with Adam Friedman, MD Adam Friedman, MD, FAAD

Adam Friedman, MD, breaks down how to say no strategically in dermatology, from delaying an answer to sharing the decision with the requester.

Ameluz Treatment Becomes First FDA-Approved PDT for Skin Cancer Tim Smith

Ameluz is now the first FDA-approved photodynamic therapy for a skin cancer, expanding use to superficial basal cell carcinoma (sBCC) in adults.

Recommended News For You

Words matter to people living with cancer. Here's how verbal microaggressions affect their mental state

Only 1 in 4 Eligible Adults Receive Lung Screening

U.S. Nurse Found Dead; Harvey Weinstein's Cancer; Creepy Source of Ear Pain

Preferred and Actual Location of Death Often Don't Match for Young Cancer Patients

Coupling dye and fiducial marking can improve precision in pulmonary nodule surgical resection

Mouse study finds tirzepatide slowed obesity-associated breast cancer growth

A novel blood test may enable the early identification of common, fatal cancers.

Recommended Articles For You

Citizen-Centered Digital Health Navigation Systems: Advancing Patient Engagement and Optimizing Healthcare Delivery 

Megakaryocyte Immune Cell Crosstalk: Mechanisms, Clinical Insights, and Therapeutic Implications 

Women's Health Through Understanding Hematologic Adaptation Across Menstrual and Reproductive Stages 

Macrocytic Anemia: A Comprehensive Review of Pathophysiology, Diagnosis, and Clinical Management 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study offers clearer picture of childhood brain tumor survival

2.

PSMA PET Beats MRI in Prostate Cancer Staging Study

3.

Targeted radiation therapy shows near-complete response in rare sarcoma patients

4.

In Sickle Cell Disease, Lovo-Cel is "Life-Changing, Transformative.".

5.

Snus Linked to Gingival Damage, Raising Safety Questions

1.

Oncology Treatment: Innovations, Education, and Clinical Practice Insights

2.

The Future of Hematology: Innovations Every Doctor Should Know

3.

Essential Applications in Oncology in Daily Practice

4.

Cancer Diagnosis in 2025: Innovations, Education, and Evolving Clinical Strategies

5.

Bispecific Antibodies in DLBCL & Myeloma: Clinical Insights for Physicians

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

1.

Navigating the Complexities of Ph Negative ALL - Part VI

2.

Navigating the Complexities of Ph Negative ALL - Part XV

3.

Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions

4.

Updates on Standard V/S High Risk Myeloma Treatment

5.

Updates on Standard V/S High Risk Myeloma Treatment- The Next Part

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot